These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 16566935)

  • 21. Safety aspects of gonadotrophin-releasing hormone antagonists in ovarian stimulation procedures: ovarian hyperstimulation syndrome and health of children born.
    Ludwig M; Katalinic A; Felberbaum RE; Diedrich K
    Reprod Biomed Online; 2002; 5 Suppl 1():61-7. PubMed ID: 12537784
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gonadotropin-releasing hormone agonist combined with a reduced dose of human chorionic gonadotropin for final oocyte maturation in fresh autologous cycles of in vitro fertilization.
    Shapiro BS; Daneshmand ST; Garner FC; Aguirre M; Thomas S
    Fertil Steril; 2008 Jul; 90(1):231-3. PubMed ID: 17981269
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Coasting and ovarian stimulation protocols in high-responder patients undergoing assisted conception].
    Merviel P; Claeys C; Héraud MH; Lourdel E; Lanta S; Barbier F; Nasreddine A
    Gynecol Obstet Fertil; 2005 Sep; 33(9):703-12. PubMed ID: 16129645
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Onset and maintenance of the luteal phase with GnRH agonists or hCG in cycles under GnRH antagonists].
    Olivennes F
    J Gynecol Obstet Biol Reprod (Paris); 2004 Oct; 33(6 Pt 2):3S24-6. PubMed ID: 15643682
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment with gonadotropin-releasing hormone (GnRH) antagonists in women suppressed with GnRH agonist may avoid cycle cancellation in patients at risk for ovarian hyperstimulation syndrome.
    Gustofson RL; Larsen FW; Bush MR; Segars JH
    Fertil Steril; 2006 Jan; 85(1):251-4. PubMed ID: 16412770
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Repeated in vitro fertilization cycle attempts in patients undergoing controlled ovarian hyperstimulation with use of gonadotropin-releasing hormone antagonists.
    Rabinson J; Ashkenazi J; Homburg R; Meltcer S; Anteby EY; Orvieto R
    Fertil Steril; 2009 Apr; 91(4 Suppl):1473-5. PubMed ID: 18937940
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome.
    Ragni G; Vegetti W; Riccaboni A; Engl B; Brigante C; Crosignani PG
    Hum Reprod; 2005 Sep; 20(9):2421-5. PubMed ID: 15890731
    [TBL] [Abstract][Full Text] [Related]  

  • 28. What is the preferred GnRH analogue for polycystic ovary syndrome patients undergoing controlled ovarian hyperstimulation for in vitro fertilization?
    Orvieto R; Meltcer S; Homburg R; Nahum R; Rabinson J; Ashkenazi J
    Fertil Steril; 2009 Apr; 91(4 Suppl):1466-8. PubMed ID: 18774558
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane-35 pre-treatment for patients with polycystic ovary syndrome: a prospective randomized study.
    Hwang JL; Seow KM; Lin YH; Huang LW; Hsieh BC; Tsai YL; Wu GJ; Huang SC; Chen CY; Chen PH; Tzeng CR
    Hum Reprod; 2004 Sep; 19(9):1993-2000. PubMed ID: 15284212
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Application of GnRH antagonist in combination with clomiphene citrate and hMG for patients with exaggerated ovarian response in previous IVF/ICSI cycles.
    Lin YH; Seow KM; Hsieh BC; Huang LW; Chen HJ; Huang SC; Chen CY; Chen PH; Hwang JL; Tzeng CR
    J Assist Reprod Genet; 2007 Aug; 24(8):331-6. PubMed ID: 17636445
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multifollicular recruitment in combination with gonadotropin-releasing hormone antagonist increased pregnancy rates in intrauterine insemination cycles.
    Gómez-Palomares JL; Acevedo-Martín B; Chávez M; Manzanares M; Ricciarelli E; Hernández ER
    Fertil Steril; 2008 Mar; 89(3):620-4. PubMed ID: 17678911
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Depot GnRH agonist versus the single dose GnRH antagonist regimen (cetrorelix, 3 mg) in patients undergoing assisted reproduction treatment.
    Roulier R; Chabert-Orsini V; Sitri MC; Barry B; Terriou P
    Reprod Biomed Online; 2003 Sep; 7(2):185-9. PubMed ID: 14567887
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of a GnRH antagonist in controlled ovarian hyperstimulation for assisted conception in women with polycystic ovary disease: a randomized, prospective, pilot study.
    Bahçeci M; Ulug U; Ben-Shlomo I; Erden HF; Akman MA
    J Reprod Med; 2005 Feb; 50(2):84-90. PubMed ID: 15755044
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mild/minimal stimulation for in vitro fertilization: an old idea that needs to be revisited.
    Zarek SM; Muasher SJ
    Fertil Steril; 2011 Jun; 95(8):2449-55. PubMed ID: 21550037
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gonadotrophin-releasing hormone-antagonist luteolysis during the preceding mid-luteal phase is a feasible protocol in ovarian hyperstimulation before in vitro fertilization.
    Fridén BE; Nilsson L
    Acta Obstet Gynecol Scand; 2005 Aug; 84(8):812-6. PubMed ID: 16026411
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does physicians' experience influence in vitro fertilization success in patients undergoing controlled ovarian hyperstimulation with GnRH antagonists?
    Orvieto R; Rabinson J; Meltcer S; Gemer O; Anteby EY; Zohav E
    Fertil Steril; 2008 Mar; 89(3):736-7. PubMed ID: 17498708
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer.
    Doldi N; Persico P; Di Sebastiano F; Marsiglio E; Ferrari A
    Gynecol Endocrinol; 2006 May; 22(5):235-8. PubMed ID: 16785142
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimizing gonadotrophin-releasing hormone antagonist protocols.
    Trew GH
    Hum Fertil (Camb); 2002 Feb; 5(1):G13-6; discussion G16-8, G41-8. PubMed ID: 11939156
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of a low gonadotrophin-releasing hormone antagonist dose in preventing premature luteinizing hormone rise during controlled ovarian stimulation.
    Tiboni GM; Palumbo P; Leonzio E; Gabriele E; Verna I; Giampietro F
    Gynecol Endocrinol; 2011 Nov; 27(11):885-9. PubMed ID: 21500992
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ovarian hyperstimulation syndrome prevention strategies: use of gonadotropin-releasing hormone antagonists.
    Griesinger G
    Semin Reprod Med; 2010 Nov; 28(6):493-9. PubMed ID: 21082508
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.